Anti-inflammatory disease-modifying treatment and short-term disability progression in SPMS

Conclusions: Our pooled analysis of the currently available disease-modifying agents used after conversion to SPMS suggests that, on average, these therapies have no substantial effect on relapse-unrelated disability outcomes measured by the EDSS up to 4 years. Classification of evidence: This study provides Class IV evidence that for patients with SPMS, disease-modifying treatment has no beneficial effect on short-term disability progression.

http://www.neurology.org/cgi/content/short/89/10/1050?rss=1

Source: Neurology - September 4, 2017 Category: Neurology Authors: Lorscheider, J., Jokubaitis, V. G., Spelman, T., Izquierdo, G., Lugaresi, A., Havrdova, E., Horakova, D., Trojano, M., Duquette, P., Girard, M., Prat, A., Grand'Maison, F., Grammond, P., Pucci, E., Boz, C., Sola, P., Ferraro, D., Spitaleri, D., Lechner-Sc Tags: Clinical trials Observational study (Cohort, Case control), Class IV, Multiple sclerosis ARTICLE Source Type: research